glp-1 receptor agonists and cardiovascular outcome trials an update outcomes in major with Effects of GLP-1 receptor agonists

Pancreatitis is a rare but serious adverse event reported with GLP-1 agonists

This pattern aligns with findings from CANVAS [42], CREDENCE [60], and DAPA-CKD [58], in which greater absolute eGFR preservation was noted in participants with higher baseline albuminuria

Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR

GLP-1s were originally developed as diabetes medications

Jos Manuel Carrascosa has participated as PI/SI and/or guest presenter and/or advisor for Almirall, Janssen, Abbvie, UCB, Boehringer-Ingelheim, Lilly, Novartis, Amgen, BMS, and Sandoz

JG is supported by the Wellcome Trust Leicestershire Healthcare Inequalities Improvement Doctoral Training Programme (223512/Z/21/Z)